Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.
2.

Conformational states of human purine nucleoside phosphorylase at rest, at work, and with transition state analogues.

Edwards AA, Tipton JD, Brenowitz MD, Emmett MR, Marshall AG, Evans GB, Tyler PC, Schramm VL.

Biochemistry. 2010 Mar 9;49(9):2058-67. doi: 10.1021/bi902041j.

3.

Loop-tryptophan human purine nucleoside phosphorylase reveals submillisecond protein dynamics.

Ghanem M, Zhadin N, Callender R, Schramm VL.

Biochemistry. 2009 Apr 28;48(16):3658-68. doi: 10.1021/bi802339c.

4.

Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase.

Saen-Oon S, Ghanem M, Schramm VL, Schwartz SD.

Biophys J. 2008 May 15;94(10):4078-88. doi: 10.1529/biophysj.107.121913. Epub 2008 Jan 30.

5.

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.

Kicska GA, Long L, Hörig H, Fairchild C, Tyler PC, Furneaux RH, Schramm VL, Kaufman HL.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4593-8. Epub 2001 Apr 3.

6.

Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice.

Arpaia E, Benveniste P, Di Cristofano A, Gu Y, Dalal I, Kelly S, Hershfield M, Pandolfi PP, Roifman CM, Cohen A.

J Exp Med. 2000 Jun 19;191(12):2197-208.

7.
8.

Mechanism of 2-aminopurine mutagenesis in mouse T-lymphosarcoma cells.

Caras IW, MacInnes MA, Persing DH, Coffino P, Martin DW Jr.

Mol Cell Biol. 1982 Sep;2(9):1096-103.

11.

Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes.

Staal GE, Stoop JW, Zegers BJ, Siegenbeek van Heukelom LH, van der Vlist MJ, Wadman SK, Martin DW.

J Clin Invest. 1980 Jan;65(1):103-8.

12.

B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.

Goday A, Simmonds HA, Morris GS, Fairbanks LD.

Clin Exp Immunol. 1984 Apr;56(1):39-48.

13.

Cloning of human purine-nucleoside phosphorylase cDNA sequences by complementation in Escherichia coli.

Goddard JM, Caput D, Williams SR, Martin DW Jr.

Proc Natl Acad Sci U S A. 1983 Jul;80(14):4281-5.

14.

Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.

Ullman B, Martin DW Jr.

J Clin Invest. 1984 Sep;74(3):951-5.

16.

Enzymes of purine metabolism in human peripheral lymphocyte subpopulations.

Massaia M, Ma DD, Sylwestrowicz TA, Tidman N, Price G, Janossy G, Hoffbrand AV.

Clin Exp Immunol. 1982 Oct;50(1):148-54.

17.

Metabolic defects in immunodeficiency diseases.

Webster AD.

Clin Exp Immunol. 1982 Jul;49(1):1-10. Review.

18.

Human purine nucleoside phosphorylase cDNA sequence and genomic clone characterization.

Williams SR, Goddard JM, Martin DW Jr.

Nucleic Acids Res. 1984 Jul 25;12(14):5779-87.

19.

Expression of a cDNA sequence encoding human purine nucleoside phosphorylase in rodent and human cells.

McIvor RS, Goddard JM, Simonsen CC, Martin DW Jr.

Mol Cell Biol. 1985 Jun;5(6):1349-57.

Supplemental Content

Support Center